Abstract
Patients with unstable angina pectoris/non-ST-elevation myocardial infarction (NSTEMI) should be treated with dual antiplatelet therapy with the use of aspirin plus either clopidogrel, prasugrel, or ticagrelor depending on the clinical circumstances as discussed in this article.
If ticagrelor is used, the dose of aspirin must not exceed 100 mg daily. Prasugrel must not be used in patients with a history of stroke or transient ischemic attack. Platelet glycoprotein IIb/IIIa inhibitors should not be used as part of triple antiplatelet drug therapy if there is an increased risk for bleeding or in non-high-risk patients such as those with a normal baseline cardiac troponin level, nondiabetics, and those aged 75 years and older in whom potential benefit may be significantly offset by the potential risk of bleeding. Clinical trial data in patients with acute coronary syndromes do not support the use of intravenous cangrelor or oral voraxapar in the treatment of these patients.
Keywords: Acute coronary syndromes, unstable angina pectoris, non-ST-elevation myocardial infarction, aspirin, clopidogrel, prasugrel, ticagrelor, glycoprotein IIb/IIIa inhibitors, cangrelor, voraxapar.
Cardiovascular & Hematological Disorders-Drug Targets
Title:Use of Antiplatelet Drugs in the Treatment of Acute Coronary Syndromes
Volume: 13 Issue: 2
Author(s): Wilbert S. Aronow
Affiliation:
Keywords: Acute coronary syndromes, unstable angina pectoris, non-ST-elevation myocardial infarction, aspirin, clopidogrel, prasugrel, ticagrelor, glycoprotein IIb/IIIa inhibitors, cangrelor, voraxapar.
Abstract: Patients with unstable angina pectoris/non-ST-elevation myocardial infarction (NSTEMI) should be treated with dual antiplatelet therapy with the use of aspirin plus either clopidogrel, prasugrel, or ticagrelor depending on the clinical circumstances as discussed in this article.
If ticagrelor is used, the dose of aspirin must not exceed 100 mg daily. Prasugrel must not be used in patients with a history of stroke or transient ischemic attack. Platelet glycoprotein IIb/IIIa inhibitors should not be used as part of triple antiplatelet drug therapy if there is an increased risk for bleeding or in non-high-risk patients such as those with a normal baseline cardiac troponin level, nondiabetics, and those aged 75 years and older in whom potential benefit may be significantly offset by the potential risk of bleeding. Clinical trial data in patients with acute coronary syndromes do not support the use of intravenous cangrelor or oral voraxapar in the treatment of these patients.
Export Options
About this article
Cite this article as:
Aronow S. Wilbert, Use of Antiplatelet Drugs in the Treatment of Acute Coronary Syndromes, Cardiovascular & Hematological Disorders-Drug Targets 2013; 13 (2) . https://dx.doi.org/10.2174/1871529X11313020008
DOI https://dx.doi.org/10.2174/1871529X11313020008 |
Print ISSN 1871-529X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4063 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Actions of Selected Cardiovascular Hormones on Arterial Stiffness and Wave Reflections
Current Pharmaceutical Design Inflammatory Biomarkers in Peripheral Artery Disease: Diagnosis, Prognosis, and Therapeutic Challenges
Current Medicinal Chemistry Umbilical Cord Tissue Mesenchymal Stem Cells: Characterization and Clinical Applications
Current Stem Cell Research & Therapy Transient Receptor Potential Channels - Emerging Novel Drug Targets for the Treatment of Pain
Current Medicinal Chemistry N-acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP): Potential target molecule in research of heart, kidney and brain
Current Pharmaceutical Design Prodrug Strategies for Antihypertensives
Current Topics in Medicinal Chemistry Innovative Strategies in In Vivo Apoptosis Imaging
Current Medicinal Chemistry Extracorporeal Lung Assist for Sepsis and Acute Respiratory Distress Syndrome
Cardiovascular & Hematological Disorders-Drug Targets Anticoagulation in Patients with Heart Failure
Cardiovascular & Hematological Agents in Medicinal Chemistry New Vectors and Strategies for Cardiovascular Gene Therapy
Current Gene Therapy Upregulated Long Non-coding RNA ALMS1-IT1 Promotes Neuroinflammation by Activating NF-κB Signaling in Ischemic Cerebral Injury
Current Pharmaceutical Design The Chromogranin A-Derived Vasostatins: New Players in the Endocrine Heart
Current Medicinal Chemistry Update in the Management of Diastolic Heart Failure
Current Vascular Pharmacology A Comprehensive Review of the Genus Pyrola Herbs in Traditional Uses, Phytochemistry and Pharmacological Activities
Current Topics in Medicinal Chemistry Role of Ca2+-Sensitive K+ Currents in Controlling Ventricular Repolarization: Possible Implications for Future Antiarrhytmic Drug Therapy
Current Medicinal Chemistry Insights Into Early and Rapid Effects of Statin Therapy after Coronary Interventions
Current Pharmaceutical Design Differential Effects of Trans and Polyunsaturated Fatty Acids on Ischemia/ Reperfusion Injury and its Associated Cardiovascular Disease States
Current Pharmaceutical Design Acute Stroke Therapy: Combination Drugs and Multifunctional Neuroprotectants
Current Neuropharmacology Editorial (Thematic Issue: Modifying Cardiovascular Risk Factors: Newer Advances in Cardiovascular Metabolism and Diagnostic Technologies)
Current Pharmaceutical Design Nitric Oxide and Protection against Cardiac Ischemia
Current Pharmaceutical Design